Scoop: J&J con­firms that the FDA put AML drug on com­plete hold

J&J tells End­points News that a bis­pe­cif­ic an­ti­body it is part­nered on with Gen­mab for acute myeloid leukemia has been put on clin­i­cal hold af­ter pa­tients in the tri­al suf­fered se­ri­ous ad­verse events.

The drug, JNJ-63709178, tar­gets both CD3 and CD123 and was in an ear­ly stage study when the hold was in­sti­tut­ed, forc­ing in­ves­ti­ga­tors to sus­pend pa­tient re­cruit­ment, ac­cord­ing to the clin­i­cal­tri­ web site. The com­plete hold, which should stop dos­ing, fol­lowed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.